Q1 Earnings Forecast for Pfizer Issued By Leerink Partnrs

Pfizer Inc. (NYSE:PFE) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Pfizer in a research report issued to clients and investors on Wednesday, December 11th. Leerink Partnrs analyst D. Risinger expects that the biopharmaceutical company will earn $0.58 per share for the quarter. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share. Leerink Partnrs also issued estimates for Pfizer’s Q3 2025 earnings at $1.05 EPS, FY2025 earnings at $2.82 EPS, FY2026 earnings at $3.14 EPS, FY2027 earnings at $3.09 EPS and FY2028 earnings at $2.73 EPS.

Several other equities research analysts have also issued reports on PFE. Guggenheim decreased their target price on Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research report on Wednesday. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Bank of America reiterated a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a research note on Tuesday. Wolfe Research assumed coverage on Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 target price on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Wednesday, October 23rd. One analyst has rated the stock with a sell rating, nine have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and a consensus price target of $32.43.

Pfizer Trading Up 0.8 %

Shares of PFE stock opened at $25.58 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market capitalization of $144.96 billion, a price-to-earnings ratio of 34.38, a PEG ratio of 0.63 and a beta of 0.65. Pfizer has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a 50-day simple moving average of $27.23 and a two-hundred day simple moving average of $28.29.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same period last year, the company earned ($0.17) earnings per share. The business’s revenue was up 31.2% on a year-over-year basis.

Institutional Trading of Pfizer

Several institutional investors and hedge funds have recently made changes to their positions in PFE. Gladius Capital Management LP raised its position in Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 38,015 shares in the last quarter. MFA Wealth Advisors LLC bought a new position in shares of Pfizer during the 2nd quarter valued at about $29,000. Quarry LP bought a new stake in Pfizer in the 2nd quarter worth approximately $31,000. Financial Connections Group Inc. bought a new stake in Pfizer in the 2nd quarter worth approximately $34,000. Finally, Teachers Insurance & Annuity Association of America purchased a new stake in Pfizer in the third quarter worth approximately $35,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insiders Place Their Bets

In related news, Director Scott Gottlieb bought 1,000 shares of the company’s stock in a transaction on Wednesday, October 30th. The stock was acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.06% of the company’s stock.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.72%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s payout ratio is presently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.